Prime Medicine, Inc. (PRME)
NASDAQ: PRME · Real-Time Price · USD
3.720
+0.320 (9.41%)
At close: Sep 5, 2025, 4:00 PM
3.790
+0.070 (1.88%)
After-hours: Sep 5, 2025, 7:59 PM EDT
Prime Medicine Revenue
Prime Medicine had revenue of $1.12M in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to $4.96M, up 739.42% year-over-year. In the year 2024, Prime Medicine had annual revenue of $2.98M.
Revenue (ttm)
$4.96M
Revenue Growth
+739.42%
P/S Ratio
95.16
Revenue / Employee
$23,182
Employees
214
Market Cap
487.70M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.98M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 5.21M | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
PRME News
- 4 days ago - Prime Medicine, Inc. (PRME) Presents At Citi's Biopharma Back To School Conference Transcript - Seeking Alpha
- 12 days ago - Prime Medicine to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 5 weeks ago - Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 5 weeks ago - Prime Medicine Announces Pricing of Public Offering - GlobeNewsWire
- 5 weeks ago - Prime Medicine Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 7 weeks ago - Cystic Fibrosis Foundation Commits Up to an Additional $24 Million for Prime Medicine to Develop Gene Editing Therapy - Business Wire
- 7 weeks ago - Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis - GlobeNewsWire